Standout Papers

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targetin... 2017 2026 2020 2023 348
  1. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study (2017)
    Toshihiko Doi, Kohei Shitara et al. The Lancet Oncology

Immediate Impact

65 standout
Sub-graph 1 of 21

Citing Papers

Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
2025 Standout
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
2025 Standout
5 intermediate papers

Works of Atsuko Kitano being referenced

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
2017 Standout

Author Peers

Author Last Decade Papers Cites
Atsuko Kitano 449 7 5 198 169 18 562
Frederike Bensch 363 352 132 24 570
Christy Osgood 341 4 122 156 19 501
Sunil Verma 334 9 2 147 152 25 648
Véronique Debien 376 1 114 149 29 510
Samuel L. Rice 185 3 1 237 200 24 623
Normando Iznaga-Escobar 310 1 3 291 190 25 599
Preeti Trisal 400 1 240 95 11 536
Koh Furugaki 399 1 141 277 20 631
Peter Sawan 313 1 88 277 19 471
Christopher Parker 156 1 205 277 28 628

All Works

Loading papers...

Rankless by CCL
2026